US00287Y1091 - Common Stock
136.465 +3.03 (+2.27%)
NYSE:ABBV (6/2/2023, 1:42:08 PM)
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. The company offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
1 N Waukegan Rd
North Chicago ILLINOIS 60064
CEO: Richard A. Gonzalez
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Let's have a look at the S&P500 stocks with an unusual volume in today's session.
An ultra-low-priced biosimilar may negatively impact both biotechs.
Here you can normally see the latest stock twits on ABBV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.